Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1247 participants.
Also called NCT03706833
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,247 participants
- Sponsor
- Registry
-
NCT03706833
-
- Other papers using this trial's data
- Impact of Residual Mitral Regurgitation and Gradient After M‑TEER: 1‑Year Outcomes From the CLASP IID Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Germany, Switzerland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03706833. Randomized; no masking; primary purpose treatment. Start 2018-11-30 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
- Acronym
- CLASP IID/IIF
- Condition
- Degenerative Mitral Valve Disease
- Condition
- Mitral Regurgitation
- Condition
- Mitral Insufficiency
- Condition
- Functional Mitral Regurgitation
- Intervention (Device)
- Edwards PASCAL System
- Intervention (Device)
- Abbott Mitraclip System
- Lead sponsor
- Edwards Lifesciences
Record details
- Record id
cardio:ct-nct03706833- Content hash
b0e5ed8afc101b2187599f51e308f9a055319554b53fb43d27f5375c6d551011